March 7th 2024
Tocilizumab-aazg (Tyenne; Fresenius Kabi) is the first approved biosimilar to tocilizumab (Actemra; Genentech) as both intravenous and subcutaneous.
Background and Key Concepts in Biosimilars: Improving Awareness and Addressing Common Concerns
1.0 Credit / Law
View More
Clinical Conversations With the Cancer Care Team: Striving for Equitable Access to Oral Anticancer Medications
1.5 Credits / Law, Oncology
View More
Child Abuse: Responsibilities and Protection of the Reporter
1.0 Credit / Law
View More
Rheumatoid Arthritis (RA): More Than a Disease of the Joints
June 1st 2017Kevin Mange, MD, MSCE, head of North America Medical Immunology at Sanofi, provides a comprehensive overview of the considerations in the treatment of rheumatoid arthritis, which carries comorbidities that affect multiple organ systems.
Read More